Oedien (Dienogest, Ethinylestradiol | Lactose Monohydrate)

Oedien, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal management of reproductive health.

• Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential.
• Regulation of menstrual cycle: helps achieve more predictable bleeding patterns and reduces menstrual flow.
• Management of ovulatory disorders: assists in establishing regular ovulation cycles in women with irregular periods.

• Oedien combines dienogest, a progestogenic agent, with ethinylestradiol, a synthetic estrogen. The combination suppresses the hypothalamic‑pituitary‑ovarian axis, preventing the mid‑cycle surge of luteinizing hormone and thereby inhibiting ovulation. It also induces cervical mucus changes that impede sperm penetration and alters the endometrial lining to reduce the likelihood of implantation.

Adverse reactions may occur with any hormonal contraceptive. The following lists reported events.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Breast tenderness: discomfort or swelling of the breasts.
• Headache: occasional tension‑type or migraine‑like pain.
• Weight change: slight increase or decrease in body weight.
• Mood changes: irritability or mood swings.
• Breakthrough bleeding: unscheduled spotting between periods.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Arterial thrombosis: clot formation in arteries, potentially causing stroke or myocardial infarction.
• Hypertension: new‑onset or worsening high blood pressure.
• Liver dysfunction: abnormal liver enzymes or cholestasis.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Visual disturbances: sudden loss of vision or eye pain.

Before prescribing Oedien, clinicians should consider several safety factors.

• Contraindicated in pregnancy: product is Category X and must not be used.
• Avoid in women with a history of thromboembolic disorders: increased risk of clot formation.
• Screen for hypertension: monitor blood pressure prior to initiation and during use.
• Assess liver function: hepatic disease may alter drug metabolism.
• Do not use in smokers over 35 years: smoking adds cardiovascular risk.
• Store at room temperature: keep in the original pack, protect from moisture and heat.

Oedien may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine): may markedly reduce contraceptive efficacy.
• Anticoagulants (e.g., warfarin): hormonal components can enhance anticoagulant effect and increase INR.

Moderate Interactions (Monitor Closely)

• Antibiotics such as tetracycline or fluoroquinolones: may slightly decrease absorption of estrogen.
• Herbal supplements like St. John's wort: can lower plasma levels of ethinylestradiol.
• Anticonvulsants (e.g., phenobarbital): may reduce hormonal concentrations, requiring additional contraceptive measures.